Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Mar
06
Today In Oncology
FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma
Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care
Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo